Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.


The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have dramatically prolonged the overall survival of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutation, but the presence of primary or acquired resistance eventually leads to therapeutic failure. Thus, how to improve the efficacy and reverse the resistance to… (More)
DOI: 10.1016/j.canlet.2016.06.002


6 Figures and Tables


Citations per Year

Citation Velocity: 57

Averaging 57 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.